R21/Matrix-M Malaria Vaccine Developed By The University Of Oxford And The Serum Institute Of India Has Been Recommended For Use By The World Health Organisation (WHO). WHO’s Independent Advisory Body, The Strategic Advisory Group Of Experts (SAGE) And The Malaria Policy Advisory Group (MPAG) Conducted A Detailed Scientific Research Before Recommendation. Adar Poonawalla, CEO Of The Serum Institute Of India Said, “For Far Too Long, Malaria Has Threatened The Lives Of Billions Of People Across The Globe, Disproportionately Affecting The Most Vulnerable Amongst Us. This Is Why The WHO Recommendation And Approval Of The R21/Matrix-M Vaccine Marks A Huge Milestone On Our Journey To Combat This Life-Threatening Disease, Showing What Exactly Can Be Achieved When The Public And Private Sector, Scientists And Researchers, All Work Together Towards A Shared Goal.” Watch The Video To Know More.